Shares of Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report) were down 4.5% on Monday . The company traded as low as $1.00 and last traded at $1.05. Approximately 5,075 shares traded hands during mid-day trading, an increase of 57% from the average session volume of 3,241 shares. The stock had previously closed at $1.10.
Vaccinex Stock Down 4.5%
The company has a 50 day simple moving average of $1.06 and a 200-day simple moving average of $1.04. The stock has a market capitalization of $2.73 million, a price-to-earnings ratio of -0.02 and a beta of 1.10.
About Vaccinex
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
See Also
- Five stocks we like better than Vaccinex
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
